Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to begin to collect information and try to learn whether or
not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with
recurrent mullerian carcinoma. We will also collect more information about the safety and
side effects of this combination of drugs. Gemcitabine and oxaliplatin are chemotherapy drugs
that kill cancer cells. Bevacizumab is a new anti-cancer drug that works to slow or stop cell
growth in cancerous tumors by decreasing the blood supply to the tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Eli Lilly and Company Genentech, Inc. Massachusetts General Hospital Sanofi-Synthelabo